S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company

Agios Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AGIO)

$22.05
-1.09 (-4.71%)
(As of 12/8/2023 ET)
Compare
Today's Range
$22.01
$23.14
50-Day Range
$19.97
$24.53
52-Week Range
$19.80
$31.87
Volume
392,101 shs
Average Volume
391,638 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.20

Agios Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
59.6% Upside
$35.20 Price Target
Short Interest
Bearish
10.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.61mentions of Agios Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$54,017 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.25) to ($4.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

657th out of 942 stocks

Pharmaceutical Preparations Industry

315th out of 448 stocks


AGIO stock logo

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Stock Price History

AGIO Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Nektar Therapeutics (NKTR) Gets a Sell from Bank of America Securities
J.P. Morgan Reaffirms Their Hold Rating on Sana Biotechnology (SANA)
Agios Pharmaceuticals Inc (8AP.BE)
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
389
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.20
High Stock Price Target
$41.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+59.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-231,800,000.00
Net Margins
-913.95%
Pretax Margin
-913.95%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$20.03 per share

Miscellaneous

Free Float
53,521,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
0.93
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Brian M. Goff M.B.A. (Age 54)
    CEO & Director
    Comp: $1.23M
  • Ms. Cecilia Jones (Age 48)
    Chief Financial Officer
    Comp: $403.36k
  • Mr. James William Burns (Age 45)
    Corporate Secretary & Chief Legal Officer
    Comp: $660.33k
  • Dr. Sarah Gheuens M.D. (Age 43)
    Ph.D., Chief Medical Officer and Head of Research & Development
    Comp: $769.2k
  • Dr. Lewis Clayton Cantley Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $50k
  • Dr. Tak Wah Mak D.Sc. (Age 77)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 70)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 67)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. T. J. Washburn Jr. (Age 42)
    Principal Accounting Officer
  • Dr. Clive Patience Ph.D. (Age 59)
    Chief Technical Operations Officer














AGIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $41.00. On average, they expect the company's share price to reach $35.20 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of 2023. Since then, AGIO shares have decreased by 21.5% and is now trading at $22.05.
View the best growth stocks for 2023 here
.

Are investors shorting Agios Pharmaceuticals?

Agios Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,020,000 shares, an increase of 6.4% from the October 31st total of 5,660,000 shares. Based on an average daily volume of 531,600 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.0% of the shares of the company are short sold.
View Agios Pharmaceuticals' Short Interest
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $0.05. The biopharmaceutical company earned $7.40 million during the quarter, compared to the consensus estimate of $7.73 million. Agios Pharmaceuticals had a negative net margin of 913.95% and a negative trailing twelve-month return on equity of 22.03%.

What ETFs hold Agios Pharmaceuticals' stock?
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (9.30%), Armistice Capital LLC (5.95%), Rock Springs Capital Management LP (4.85%), JPMorgan Chase & Co. (4.42%), Northern Trust Corp (1.10%) and Deutsche Bank AG (1.04%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AGIO) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -